What Is Diminished Ovarian Reserve? What the Tests Do and Do Not Tell You (2026)

Diminished ovarian reserve means the ovaries hold fewer remaining eggs than expected for a woman's age. It is a statement about quantity. It is not a statement about whether those eggs can produce a healthy embryo.

That distinction carries most of the weight in this article. Reserve is estimated from two markers — anti-Müllerian hormone in a blood sample, and antral follicle count on an ultrasound scan. Both count follicles. Neither inspects what is inside them.

• Reserve = how many eggs remain.
• Quality = the chance an egg makes a chromosomally normal embryo.
• AMH and AFC measure the first and say almost nothing about the second.
• Age is the strongest available proxy for the second.

Our explanation of what AMH does and does not measure covers the marker itself in more detail, and egg quality and age covers the other half.

There is no single agreed number. Three different frameworks are in common use, they were built for different purposes, and they give different cut-offs — which is why two clinics can read the same result differently.

ESHRE's Bologna criteria, published in Human Reproduction in 2011, define poor ovarian response as at least two of three features present.

• Advanced maternal age (≥40 years) or any other risk factor for poor response.
• A previous poor response (≤3 oocytes with a conventional stimulation protocol).
• An abnormal ovarian reserve test — AFC <5–7 follicles or AMH <0.5–1.1 ng/mL.

The POSEIDON framework, introduced in 2016, uses a single pair of thresholds — AMH below 1.2 ng/mL or AFC below 5 — and then splits patients by age, group 3 being under 35 and group 4 being 35 and over. It was designed to plan stimulation, not to deliver a prognosis.

Two things follow from having three frameworks rather than one. A result can be abnormal under POSEIDON and unremarkable under Bologna. And none of these numbers was ever validated as a threshold for whether to try.

• Fertility Myths vs Facts: Ten Claims Checked Against the Evidence
• IVF Side Effects: What OHSS Is and How It Is Prevented
• After a Failed IVF Cycle: What Is Worth Investigating
• What Is AMH and Why It Matters?
• Fertility Tests for Women: What Each One Checks, and When
• PCOS and Fertility — How It Affects Conception and What Works (2026)
• IVF Success Rates: How to Read the Numbers You Are Quoted

No, and this is the clearest finding in the field. ASRM's 2020 committee opinion states plainly that results of ovarian reserve tests are not useful in predicting the likelihood of unassisted pregnancy in women with infertility.

For women without an infertility diagnosis the evidence is stronger still. Steiner and colleagues followed 981 women aged 30 to 44 with no history of infertility, publishing in JAMA in 2017.

Women with low AMH were no less likely to have conceived by cycle six or cycle twelve than women with normal levels. The marker that predicts how a stimulation cycle will go did not predict whether these women got pregnant on their own.

What AMH does predict, and predicts well, is egg yield. ASRM puts it directly: the ability of AMH and AFC to predict oocyte yield as well as poor and excessive response to gonadotropin stimulation has been well demonstrated. That is a genuinely useful thing to know before a cycle. It is a different question from the one most people are asking when they open the result.

It changes cycle planning rather than the decision to have a cycle. Fewer eggs collected means fewer embryos to work with, which affects protocol choice, dosing and how many cycles it may take.

• Protocol and dose are usually adjusted upward or switched.
• Expected egg numbers per retrieval are lower.
• Reaching a given number of embryos may take more than one retrieval.
• Time matters more, because reserve declines and age keeps moving.

What it does not change is the chromosomal competence of the eggs that are collected, which tracks with age rather than with reserve. A woman of 32 with low AMH and a woman of 42 with normal AMH are not in the same position, and the reserve result is the less informative of the two facts.

Which protocol suits a lower responder is a clinical decision with real trade-offs — our comparison of antagonist and agonist protocols sets out what the trials show.

A useful test for any claim about ovarian reserve is to ask whether it is about how many eggs there are, or about what they are worth. Most misleading claims quietly swap one for the other.

• A low AMH is not a diagnosis of infertility.
• A reassuring AMH at 41 does not change the odds that age sets.
• No reserve marker has been validated as a reason to decline treatment.
• No supplement has been shown to raise AMH in a way that improves live birth.

Reserve testing was built to help plan a stimulation cycle, and within that job it works. The harm comes from carrying the number outside that job — into conversations about whether to try at all, which is the one place ASRM says it does not belong.

Comparing centres locally helps: our directory covers fertility clinics in Vijayanagar, each with an IVY Score built from the same five signals, alongside the other 37 areas of the city.